A Retrospective Analysis of Raltegravir Use in Minority HIV Infected Women in Houston, Texas
- Conditions
- HIV Infection
- Interventions
- Registration Number
- NCT02302950
- Brief Summary
Raltegravir is the first marketed strand-transfer inhibitor of HIV-1 that was FDA approved in 2007. It is currently one of the preferred treatment regimens for HIV by the Department of Health and Human Services. It has become a widely used antiretroviral therapy option for HIV infected patients. It provides good tolerability and a favorable lipid profile for patients when compared to some other antiretroviral treatment options. Little data is reported about efficacy in a minority patient population. Moreover, data in an indigent minority population in the United States has not been aggregated before. Therefore this study will investigate the efficacy of raltegravir in minority women residing in Houston, TX who are HIV infected.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- Female
- Target Recruitment
- 254
- HIV-infected women who picked up raltegravir in the year 2013 at Thomas Street Health Center.
- Minority women -Black/African American, Hispanic/Latino
- n/a
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description women that picked up raltegravir 2013 raltegravir minority women that picked up raltegravir at Thomas street Health Center 2013
- Primary Outcome Measures
Name Time Method Assess the efficacy of raltegravir in study participants by measuring CD4 count and viral load 24 weeks of therapy
- Secondary Outcome Measures
Name Time Method Capture data on concomitant conditions that may have led to participants switching to raltegravir from medical records (eg. Diabetes mellitus) 24 weeks of therapy Assess tolerability of raltegravir by capturing symptoms 24 weeks of therapy
Trial Locations
- Locations (1)
Thomas Street Clinic
🇺🇸Houston, Texas, United States